Gavi Purchases 500,000 Mpox Vaccines for Africa Amid Global Health Emergency

Gavi will buy 500,000 doses of Bavarian Nordic's mpox vaccine to combat an outbreak in Africa, mainly affecting the Democratic Republic of Congo. The purchase, costing up to $50 million, includes logistics and administration. This move aims to expedite vaccinations and build a global vaccine stockpile.

The global vaccine alliance Gavi has announced its first purchase of 500,000 doses of Bavarian Nordic's mpox vaccine to address a worsening outbreak in Africa. The Democratic Republic of Congo has reported more than 25,000 suspected cases and 723 deaths this year, according to the World Health Organization.

This $50 million initiative by Gavi aims to cover not only the cost of the vaccine but also transportation, delivery, and administration. The vaccines are expected to be delivered promptly within this year. Despite a pledge of 3.6 million doses by wealthy nations, only a small fraction has reached the DRC so far.

By utilizing a new facility established post-COVID-19, Gavi seeks to accelerate responses to public health emergencies. The price per vaccine is tentatively estimated around $100, though the true cost remains undisclosed due to the inclusion of logistics and rollout expenses. Gavi's CEO emphasized the importance of rapid deployment and building a global stockpile for future needs.

(With inputs from agencies.)